Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780373 | 0.96 | L3MBTL1 (0.49) | NQO1LMNAL3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL29629327 | 0.87 | NQO1 (0.68) | NQO1L3MBTL1AKR1C3AKR1C2CA12 | |
| SCHEMBL3825385 | 0.87 | NQO1 (0.68) | NQO1L3MBTL1AKR1C3AKR1C2CA12 | |
| SCHEMBL30334792 | 0.84 | CA12 (0.50) | LMNAL3MBTL1AKR1C2CA12CA1 | |
| SCHEMBL1608519 | 0.84 | CA12 (0.50) | LMNAL3MBTL1AKR1C2CA12CA1 | |
| SCHEMBL4057003 | 0.84 | CA12 (0.50) | LMNAL3MBTL1CA12CA1CA6 | |
| SCHEMBL4063865 | 0.83 | NCF1 (0.57) | LMNAL3MBTL1NCEH1MAOBMAPT | |
| SCHEMBL23458226 | 0.82 | NQO1 (0.62) | NQO1L3MBTL1AKR1C3AKR1C2CA12 | |
| SCHEMBL3821099 | 0.82 | NQO1 (0.62) | NQO1L3MBTL1AKR1C3AKR1C2CA12 | |
| SCHEMBL29779700 | 0.82 | NQO1 (0.62) | NQO1L3MBTL1AKR1C3AKR1C2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853261-B1 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES | UNIV SAARLAND (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-8071598-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-12-06 | — | — | US | disclosed |
| EP-2318420-A1 | SOLUTION PROCESSABLE ORGANIC SEMICONDUCTORS | 3M Innovative Properties Company (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20110079775-A1 | Solution Processable Organic Semiconductors | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-07 | — | — | US | disclosed |
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | ANIONA APS (DK) | 2010-06-24 | — | — | US | disclosed |
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| US-7700596-B2 | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-20 | — | — | US | disclosed |
| WO-2009154877-A1 | SOLUTION PROCESSABLE ORGANIC SEMICONDUCTORS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| US-5912256-A | 0-(4-INDOLYLOXY)-3-(4-HYDROXY-4-NAPHTHYLPIPERIDIN-1-YL)PROPANE S | ELI LILLY AND COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
| US-5820781-A | Naphthyl organic compounds | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN & NORTHERN IRELAND (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0814084-A1 | Indole derivatives as 5-HT1A antagonists and as inhibitors of serotonine reuptake | ELI LILLY AND COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1997048698-A1 | COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5496500-A | LIQUID CRYSTALS; ELECTROOPTICS DISPLAY DEVICES; DROPLETS DISPERSED IN TRANSPARENT POLYMER MATRIX | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN & NORTHERN IRELAND (GB) | 1996-03-05 | — | — | US | disclosed |
| EP-0531475-A1 | NAPHTHYL ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN (GB) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992016500-A1 | NAPHTHYL ORGANIC COMPOUNDS | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-01 | — | — | WO | disclosed |
| US-5084204-A | Naphthylacetylenes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-01-28 | — | — | US | disclosed |
| US-4137272-A | Process for the manufacture of 2-alkoxy-6-bromo-naphthalenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160333-A1 | NOVEL 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A3, SLC6A2 | NQO1 1021/4885LMNA 4279/4885L3MBTL1 4856/4885 |
| US-20110079775-A1 | Solution Processable Organic Semiconductors | ESPL1, TST, SPIN3 | NQO1 1230/4885LMNA 1843/4885L3MBTL1 1891/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | NQO1 1770/4885LMNA 1959/4885L3MBTL1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.